The exquisite sensitivity of HR to RAD52 splicing perturbations highlights the therapeutic potential of targeting succinylation-dependent AS nodes to disrupt DDR adaptation in radioresistant HCC. This evidence concerns the gene RAD52 and hepatocellular carcinoma.